hiTDExs PKM2 were found to exhibit PKM2-BCL2 mediated anti-apoptotic activity and inhibit cisplatin-mediated apoptosis in non-small cell lung cancer (NSCLC) cells. Here, BCL2 is linked to non-small cell lung carcinoma.